The convergence of cardioprotective intracellular signalling pathways to modulate mitochondrial function as an endtarget of cytoprotective stimuli is well described. However, our understanding of whether the complementary changes in mitochondrial energy metabolism are secondary responses or inherent mechanisms of ischaemic cardioprotection remains incomplete. In the heart, the malate-aspartate shuttle (MAS) constitutes the primary metabolic pathway for transfer of reducing equivalents from the cytosol into the mitochondria for oxidation. The flux of MAS is tightly linked to the flux of the tricarboxylic acid cycle and the electron transport chain, partly by the amino acid L-glutamate. In addition, emerging evidence suggests the MAS is an important regulator of cytosolic and mitochondrial calcium homeostasis. In the isolated rat heart, inhibition of MAS during ischaemia and early reperfusion by the aminotransferase inhibitor aminooxyacetate induces infarct limitation, improves haemodynamic responses, and modulates glucose metabolism, analogous to effects observed in classical ischaemic preconditioning. On the basis of these findings, the mechanisms through which MAS preserves mitochondrial function and cell survival are reviewed. We conclude that the available evidence is supportive of a down-regulation of mitochondrial respiration during lethal ischaemia with a gradual 'wake-up' during reperfusion as a pivotal feature of ischaemic cardioprotection. Finally, comments on modulating myocardial energy metabolism by the cardioprotective amino acids glutamate and glutamine are given.
Introduction
The heart is a metabolic omnivore, capable of utilizing multiple fuel sources to satisfy its enormous daily energy demands of 6 kg of ATP, a mass 20 times its own. 1 A dynamic, competitive interaction between myocardial glucose and fatty acid oxidation has been recognized since the concept of a 'glucose-fatty acid cycle' was proposed by Randle et al. 2 .40 years ago, and is documented in experimental and human studies. 3, 4 While fatty acids constitute the predominant fuel of the normal heart, the ischaemic myocardium has a preference for glucose oxidation. Theoretically, this metabolic adaptation is beneficial because glucose oxidation is more 'oxygen efficient' than fatty acid oxidation, with a complete switch to glucose reducing oxygen demand by 11 -13%. 5 Despite this, large clinical trials in recent
years have failed to demonstrate any discernible benefit of glucose, insulin, and potassium infusion in acute myocardial infarction. 6 -8 Notably, persuasive data from the same studies indicate that the circulating glucose level is a strong predictor of clinical outcome, 9 emphasizing the importance of disturbed glucose homoeostasis in ischaemic heart disease. We have been unable to demonstrate any clinical benefit on cardiac function after modulation of the availability of glucose and free fatty acids by insulin-glucose and somatostatinheparin infusions in patients with chronically ischaemic stunned or hibernating myocardium, 10 or by long-term reduction in circulating fatty acids mediated by the nicotinic acid derivative acipimox in heart failure patients. 11 These data suggest that the diseased heart is capable of adaptation to extreme variations in the circulating substrate supply, but in our opinion clinical improvement of cardiac function by changing the circulating concentrations of glucose and fatty acids per se has not been convincingly documented.
Favourable clinical effects of a metabolic or pharmacological mediated shift from free fatty acid to glucose utilization at the mitochondrial level have been reported in small studies of patients. 12 Increased glucose oxidation through activation of the mitochondrial pyruvate dehydrogenase complex (PDH) by dichloroacetate reversed contractile dysfunction of the post-ischaemic isolated heart independent of the glycolytic rate and glycogen metabolism. 13 Similarly, in eight heart failure patients, intracoronary infusion of pyruvate-induced improvement in cardiac function. 14 In a randomized study of 56 heart failure patients, reduction of mitochondrial fatty acid uptake by perhexiline, an inhibitor of carnitine palmitoyl transferase-1, improved left ventricular (LV) function. 15 However, the effect of fatty acid oxidation modulation remains complex, and it is controversial whether suppression of fatty acid oxidation is beneficial or detrimental, 16 as are the effects of activators of the peroxisome proliferator-activated nuclear receptors. 17 In mammalian tissues, cellular redox and bioenergetic states are regulated by metabolic NADH shuttles that facilitate the transfer of reducing cytosolic equivalents across the inner mitochondrial membrane into the mitochondria for oxidation. The major shuttles are the a-glycerophosphate shuttle and the malate-aspartate shuttle (MAS), first proposed by Borst 18 in 1962. MAS is the dominant shuttle in the heart. 19, 20 We have reported that blockade of MAS by the amino acid transaminase inhibitor aminooxyacetate (AOA) during ischaemia and the start of reperfusion yields cardioprotection against ischaemia-reperfusion (IR) injury similar in character and magnitude to the effect of ischaemic preconditioning (IPC) including reduced infarct size and an improved post-ischaemic haemodynamic response. 21 Paradoxically, sustained AOA inhibition of MAS during reperfusion has detrimental effects, including increased infarction and a diminished haemodynamic recovery. 22 In this review, we attempt to summarize the scant and fragmented evidence concerning changes in the MAS flux in relation to ischaemic cardioprotection. In addition, certain 'fingerprints' of myocardial energy metabolism of possible importance in response to ischaemic conditioning are discussed.
Mitochondria and ischaemic cardioprotection
It is well documented that mitochondria are one of the end-effectors of ischaemic cardioprotection. 23, 24 Mitochondrial mechanisms of IR injury and the targets of cardioprotection include Ca 2+ overload, oxidative stress with formation of reactive oxygen species (ROS), and involvement of ATP-dependent potassium channels leading to disruption of the inner mitochondrial membrane and opening of the nonspecific permeability transition pore (mPTP) complex causing cell death (for review, see Di Lisa et al. 25 and Boengler et al.
26
). Except for a few select metabolites and ions, the inner mitochondrial membrane is impermeable. This ensures maintenance of the membrane potential and the pH gradient that drives oxidative phosphorylation and ATP synthesis. 23 IPC and postconditioning (IPostC) activate inherent cardioprotective mechanisms against IR injury and cell death by applying repeated short cycles of ischaemia and reperfusion before or after sustained lethal ischaemia. 27, 28 Among other mechanisms, IPC and IPostC both mediate protection by inhibition of opening of the mPTP. 29, 30 Impermeability of the inner mitochondrial membrane to the pyridine dinucleotides NAD and NADH was first described by Lehninger 31 in 1951, but the opening of the mPTP pore causes efflux from the mitochondrial matrix of several substances including NAD. 32 Our studies on the effects of AOA inhibition of MAS on cardioprotection 21, 22 were driven by the hypothesis that ischaemic damage to the permeability barrier of the inner mitochondrial membrane disturbs the metabolic flux through MAS. Extensive research has focused on intracellular signalling pathways, an issue outside the scope of this paper and reviewed recently. 33 -35 Two overall protective signalling pathways have been identified, the reperfusion injury salvage kinase pathway, and the recently described survivor activating factor enhancement pathway. 36 Figure 1 ). The enzymes of the shuttle co-localize with enzymes of the tricarboxylic acid (TCA) cycle located at the inner mitochondrial membrane. 40 Furthermore, the MAS shares intermediates with the TCA cycle (oxaloacetate, malate, a-ketoglutarate) and the electron transport chain (ETC; glutamate, malate) ensuring a tight co-ordination between shuttle activity and mitochondrial respiration. The unique feature of the MAS is the cytosolic and Figure 1 Outline of the MAS. Green: Ca
2+
-activated AGC; blue: OMC. Aspar, aspartate; AST, aspartate amino transferase; a-kglut, a-ketoglutarate; Glut, glutamate; MDH, malate dehydrogenase; OAA, oxaloacetate; net shuttle result is transfer of cytosolic NADH to the mitochondrial matrix.
Malate-aspartate shuttle in cardioprotection mitochondrial AST reactions. Aminotransferase reactions are not directly involved in the TCA cycle nor in the ETC.
Transport of MAS metabolites across the inner mitochondrial membrane occurs via two antiporters, the reversible electroneutral oxyglutarate (a-ketoglutarate)/malate carrier (OMC) and the electrogenic and energy-dependent aspartate/glutamate carrier (AGC) which mediates the efflux of aspartate in exchange for mitochondrial uptake of glutamate, driven by the membrane potential ( Figure 1 ). AGC controls flux through MAS and contributes to an asymmetric distribution of NADH between the cytosolic and mitochondrial compartments. 20 Cardiac AGC consists of two proteins, aralar (also named AGC1) and citrin (AGC2), with aralar as the predominant isoform. 41 Both carrier proteins have been demonstrated in the human heart, 42 whereas mitochondria in the brain and skeletal muscles only express aralar, and in the liver, citrin (to accommodate the urea cycle). Glutamate transport across the inner mitochondrial membrane is a key function of the MAS. Ralphe et al. 43 have reported expression of the brain excitatory amino acid glutamate transporter (EAAT1) in cardiac mitochondria, localized at the inner mitochondrial membrane. Over expression of EAAT1 leads to increased MAS flux as seen in hyperthyroidism which increases EAAT1 expression and MAS activity in parallel. 44 We have reported decreased EAAT1 expression in the Zucker diabetic fatty rat heart at the onset of diabetes. 45 Any interplay between mitochondrial uptake of glutamate by the AGC carrier and EAAT1 has yet to be described.
Paradoxical effects of MAS inhibition during ischaemia and reperfusion
AOA is a reversible inhibitor of pyridoxal-dependent enzymes including cytosolic and mitochondrial ASTs. As such, AOA is well established in its use as a pharmacological tool to evaluate the operation of the MAS in a multiplicity of tissue types including the heart, 46 liver, 47 brain, 48 kidney, 49 and pancreatic b-cells. 50 AOA inhibition of the MAS mediates a reversible dose-dependent depression of LV function of the isolated non-ischaemic heart, 22 and depresses myocardial and vascular glucose oxidation. Down-regulation of pyruvate oxidation results in increased glycolysis, glycogenolysis, and lactate production despite an adequate oxygen supply from the circulation, in essence increased aerobic glycolysis. 21, 51 Chemical inhibitors of the ETC complexes improve post-ischaemic recovery from IR injury. 52, 53 This is somewhat paradoxical given that mitochondrial respiration is already inhibited during ischaemia. However, the idea that a gradual metabolic 'wake-up' of mitochondrial respiration during early reperfusion mediates cardioprotection by avoiding oxygen stress with an abrupt burst of ROS production and calcium overload at the start of reperfusion gains support from these findings. 52 Although the effect of IPC as well as chemical blockade of the ETC complexes converge at the mitochondria, the role per se of inhibition of the ETC complex by IPC remains controversial. 54 In isolated mitochondria from the aerobically perfused rabbit heart, AOA suppresses oxygen consumption at complex I of the ETC. 21 From this, we hypothesized that AOA loading of the heart prior to exposure to global no-flow ischaemia resulting in inhibition of mitochondrial respiration during sustained ischaemia and early reperfusion, the period in which we assumed AOA inhibition of the MAS to be active, would induce cardioprotection similar to the protective effect of classical IPC. Pre-ischaemic AOA loading of the heart reduced infarct size, improved haemodynamic recovery, and modulated glycolysis and glucose oxidation during the first 20 min of post-ischaemic reperfusion in a form and extent similar to IPC's. In contrast, continuous AOA treatment, extended to 2 h of reperfusion diminished postischaemic ventricular salvage with a dose-dependent increase in infarct size and impaired haemodynamic recovery. 22 However, the haemodynamic response to AOA differed markedly during early and late reperfusion with a superior recovery during the first 15 -20 min that exceeded the effect of IPC ( Figure 3) . We have found similar responses after AOA administration during post-ischaemic reperfusion of hearts protected by IPostC (unpublished data). The above in vitro findings are subject to limitations. The rat heart model was perfused with glucose as the only substrate to evaluate the role of the MAS in ischaemic cardioprotection. AOA inhibition of MAS affects myocardial oxidation of glucose without any effect on fatty acid oxidation, 51, 55 and our data support the concept that basal glucose oxidation and MAS activity are essential during longterm post-ischaemic reperfusion. 3 Perfusion with a high free fatty acid concentration has been reported to compromise post-ischaemic recovery and promote contracture and ROS production.
56,57
However, we have not observed any influence on AOA-mediated cardioprotection after perfusion of the heart with physiological concentrations of free fatty acids (0.4 mM; unpublished data). It needs to be emphasized that AOA is a non-specific inhibitor of several aminotransferases outside the MAS. 58 
aspartate is a more selective inhibitor of the ASTs that mediates similar but irreversible effects as AOA on glucose metabolism of brain tissue. 59 ,60 D-Cycloserine inhibits only the cytosolic but not the mitochondrial AST, and also inhibits alanine aminotransferase. 61 Although chemical substances other than AOA may provide additional information about the MAS flux, off-target effects cannot be excluded for any inhibitor studied. Taken together, the cardioprotective effect seen with inhibition of the MAS during no-flow ischaemia and early reperfusion provides convincing evidence that a down-regulation of mitochondrial respiration constitutes a pivotal mechanism for protection against IR injury.
MAS and cellular calcium homoeostasis
The relation between the metabolic flux of MAS and cellular Ca 2+ homoeostasis is intriguing. The AOA-mediated changes of LV diastolic pressure during no-flow ischaemia and of left ventricular developed pressure (LVDevP) at the start of reperfusion may reflect a significant regulatory effect by the MAS on myocardial calcium homoeostasis. The synergistic effect of the combined intervention of AOA and IPC in normalizing diastolic pressure during global ischaemia adds further support to this hypothesis (Figures 2 and 3 ).
Mitochondrial calcium and MAS
Several extensive reviews on mitochondrial calcium handling have been published recently. 62 -64 The discovery of the AGC carrier proteins aralar and citrin 62 indicates that not only intra-mitochondrial but also extra-mitochondrial Ca 2+ regulates oxidative phosphorylation.
Aralar mediates mitochondrial uptake of calcium and glutamate,
which is subsequently oxidized in the TCA cycle and ETC. 64, 65 Calcium activation of isolated heart mitochondria requires the presence of glutamate but not of pyruvate or succinate. 64 In addition, glutamate increases contraction frequency and intracellular Ca 2+ oscillations in cultured rat myocytes. 66 The calcium-dependent AGC has been characterized as a mitochondrial 'gas pedal' that supplies oxidative phosphorylation with substrate on demand. 64 In the brain, in silico simulations have reported very close correlations between the flux of the MAS and oxidative phosphorylation in glial cells and neurones with low and high MAS activity, respectively.
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For decades, mitochondria have been known to accumulate and release Ca 2+ by the so-called mitochondrial Ca 2+ uniporter (mCU), 68 and an Na + -dependent and Ca 2+ -independent antiporter, respectively. 69 Mitochondrial [Ca 2+ ] is a strong activator of oxidative phosphorylation through activation of key enzymes of the TCA cycle, including pyruvate dehydrogenase, isocitrate dehydrogenase, and a-ketoglutarate dehydrogenase (a-KGDH), and also of F O / F 1 -ATPase ATP production. 70 Intra-mitochondrial calcium activation of the a-KGDH reaction is thought to mediate a reversible inhibition of the OMC and MAS due to competition for the shared substrate a-ketoglutatrate (a-KG) between MAS and TCA cycle. Lewandowski et al. 71 and Ó Donnell et al. 72 have reported experimental evidence for inhibition of the MAS by this mechanism in both the post-ischaemic reperfused isolated heart as well as hearts exposed to high workloads. 73 Contreras and Satrústegui 74 have proposed sequential activation of the mCU/ matrix dehydrogenase and the AGC pathways in brain and heart mitochondria. However, the complexity of mitochondrial Ca 2+ signalling for co-ordination of mitochondrial ATP production and cardiac contractility is still only partly delineated. 63 Most results have been obtained on isolated mitochondria and may well differ from the conditions in the perfused beating heart. 64 Furthermore, the nature of mCU remains to be identified. Although older studies 75 have questioned whether the capacity of the MAS is of physiological importance in the aerobic heart, our results suggest that the MAS-mediated link between intermediary cellular metabolism and intracellular Ca 2+ homoeostasis is a significant regulatory mechanism during cardiac IR.
AOA effects on LV diastolic pressure during no-flow ischaemia
During the first 10 min of no-flow ischaemia-a situation without calcium overload-AOA, IPC, and their combination induce an abrupt increase in diastolic pressure, which may reflect an increase in cytosolic [Ca 2+ ] secondary to inhibition of the AGC by MAS (Figure 2) . In silico studies have calculated that myocardial MAS flux decreases to almost zero at the onset of severe ischaemia. 76 During sustained ischaemia diastolic pressure remained elevated in AOA-treated heart as in control hearts, while the combination of AOA and IPC normalized the diastolic pressure of IPC hearts consistent with a reduction of cytosolic [Ca 2+ ]. At present, no explanation of this unexpected beneficial finding can be given. An augmented mitochondrial Ca 2+ uptake seems most unlikely because a high matrix [Ca 2+ ] is a deleterious phenomenon incompatible with cardioprotection. 77 Our metabolic In transgenic animal models, over expression of SERCA reduces IR injury, 81 while SERCA deficiency increases infarct size. 82 The SERCA2a-stimulating drug istaroxime improves myocardial contractility and relaxation in atrial biopsies from heart failure patients. 83 
AOA effects on LVDevP during early and late reperfusion
It is notable that an inhibition of MAS by AOA during early reperfusion (first 20 min) mediated increases in LVDevP that exceeded the recovery of both control and IPC hearts (Figure 3 ). At present, the underlying mechanisms are speculative. Provided that AOA has no effect on the SR handling of Ca 2+ , which to our knowledge has not been studied, the early increases in LVDevP likely reflect an increase in extra-mitochondrial [Ca 2+ ] secondary to an AOA inhibition of mitochondrial Ca 2+ uptake by AGC. Impaired SERCA-mediated Ca 2+ uptake into the SR contributes to the cellular Ca 2+ overload during early post-IR. 84, 85 It is of interest that inhibition of mitochondrial Ca 2+ uptake by blockade of mCU with ruthenium red or an analogue has been reported to improve haemodynamic recovery of the post-ischaemic heart. 86 Caldaret, a novel drug, that enhances calcium uptake into and inhibits calcium leakage from the SR reduced LV dysfunction when given as an adjunctive treatment to primary percutaneous coronary angioplasty in high-risk patients with large anterior infarction and/or a totally occluded target vessel. 87, 88 Delayed normalization of ischaemic tissue acidosis during early reperfusion inhibits opening of the mPTP and is a well-documented underlying mechanism of cardioprotection by both IPostC and IPC. 89, 90 Although evidence is currently lacking, we conjecture that part of the cardioprotective effect of AOA inhibition of MAS during early reperfusion includes a delay in the normalization of the cellular acidosis during reperfusion by inhibition of proton transport from the cytosol to the mitochondria. Supporting this, activity of the AGC of MAS includes an obligatory transport of protons into the mitochondrial matrix 41 ( Figure 1 ).
Although it is established that IPC reduces the production of reactive oxidative species during reperfusion, 91, 92 ROS appear to play both a detrimental and signalling role. Administration of the ROS scavenger N-mercaptopropionylglycine during reperfusion abolishes cardioprotection in IPC-subjected hearts. 93 We have reported an AOA-mediated reduction in myocardial ROS production in the nonischaemic heart, 21 but studies on the effect of AOA on ROS production in the ischaemic/reperfused heart are urgently required.
The abrogation of post-ischaemic haemodynamic recovery after continuous AOA perfusion during late reperfusion (40-120 min, Figure 3 ) was not unexpected due to the critical role of MAS activity and glucose oxidation during reperfusion as mentioned previously. Continuous AOA administration during reperfusion increases infarct size in a dose-dependent manner. 22 Recently, over expression of SERCA1 has been found to normalize the disturbed relation between TCA cycle flux and cardiac function in the calcium-overloaded, stunned myocardium, an effect hypothesized to include an improvement of NADH transport into the mitochondria during late reperfusion. 94 Taken together, the significant haemodynamic responses of AOA inhibition of the MAS during no-flow ischaemia and reperfusion support a role of the MAS in ischaemic cardioprotection by modulating intra-and extra-mitochondrial [Ca 2+ ]. We hypothesize that the modulation of myocardial Ca 2+ homoeostasis by the MAS occurs in parallel with and closely coupled to its effect on oxidative phosphorylation. In other words, AOA inhibition of the MAS during ischaemia ensures that the mitochondrial engine stays in 'idle running' when in lack of its main fuel, oxygen. Washout of AOA from the loaded ischaemic heart requires 5 min of reperfusion, 21 which ensures a retained inhibition of the MAS during the first few minutes of reperfusion generating a gradual 'wake-up' of oxidative phosphorylation. In contrast, continuous AOA administration during late reperfusion degrades 'engine power' by demounting the mitochondrial 'gas pedal' when most needed.
Metabolic aspects of cardioprotection

Ischaemic glucose metabolism and the MAS
Following the initial activation of anaerobic glycolysis with lactate production, persistent ischaemia inhibits both glycolysis and glycogenolysis. IPC accentuates this inhibition 95, 96 and also enhances post-ischaemic glycogen resynthesis. 97 The underlying mechanism of glycolytic inhibition is multi-factorial and not fully elucidated but is likely mediated by accumulation of glycolytic metabolic end-products that modulate the allosteric control of the pathway and/or modify the glycolytic enzyme properties. 96 A cardioprotective effect of the inhibited glycolysis seen in IPC hearts has been attributed to a reduction in ischaemic tissue acidosis. 97, 98 At the start of reperfusion, protons are rapidly removed from the acidotic cell by the Na + /H + exchanger, which promotes intracellular Na + accumulation with reverse mode activity of the sarcolemmal Na + /Ca 2+ exchanger resulting in cytosolic Ca 2+ overload, leading to an increased risk of hypercontracture and ultimately cell death. 99, 100 This mechanism is also considered to be of major importance in IPostC, as reviewed elsewhere. 101 It probably constitutes a common protective mechanism behind mechanical and pharmacological conditioning modalities that reduces tissue acidosis through inhibition of the glycolytic pathway. Hence, our finding that inhibition of the MAS by AOA reduces myocardial lactate accumulation during ischaemia and tracer-estimated glycolytic flux during reperfusion to the same extent as classical IPC 21, 22 unveils an underlying metabolic pathway of cardioprotection. Calcium activation of the mitochondrial PDH 102 stimulates glucose oxidation during post-ischaemic reperfusion and has been proposed T.T. Nielsen et al.
as the regulatory mechanism responsible for glucose preference to fatty acid oxidation during early reperfusion. 94, 103 The finding that not only IPC, but also pre-ischaemic AOA administration increased post-ischaemic glucose oxidation above that of control hearts during the first 20 min of reperfusion demonstrates that both interventions are able to 'kick-start' energy metabolism through common mechanisms. It has been speculated whether anaplerotic carboxylation of pyruvate to malate and oxaloacetate by the malic enzyme is involved in cardioprotection. Anaplerotic influx of carbon into the TCA cycle by this pathway operates in immature 104 and hypertrophied hearts 105 but is low in the adult heart and decreases during ischaemia. 106, 107 The increased interstitial pyruvate concentration seen during ischaemia in AOA-loaded hearts 21 does not support anaplerotic conversion of pyruvate as a predominant mechanism, but rather points towards augmented pyruvate oxidation through the activated PDH reaction.
Cardioprotective effects of glutamate
L-Glutamate plays an important role in the cellular coupling of cytosolic and intra-mitochondrial energetic states, at least partly mediated through the MAS. The physiological roles of glutamate are very diverse, and it has been known to possess cardioprotective effects for several years. 108 Supraphysiological concentrations of glutamate (and aspartate) are used as metabolic additives in cardioplegic solutions to improve the post-operative contractile function of the heart in patients undergoing cardiac surgery. 109, 110 The human heart extracts glutamate from the circulation in larger quantities than any other amino acids, and this uptake is further enhanced in the chronically ischaemic heart. 4, 111 Myocardial glutamate content is three to four times higher than that of lactate, and 50-fold higher than the plasma concentration, 112 indicating that cellular synthesis of glutamate is a main determinant of the tissue concentration. It is essential to keep the low circulating glutamate concentration (50-100 mM in humans) constant without diurnal variation. 113 Glutamate administration in humans may cause mental disturbances like the 'Chinese Restaurant Syndrome', 114 and a moderate increase in plasma glutamate induces an instant release of insulin from the pancreatic b-cells.
115
Our knowledge of the effects of glutamate at the cellular level is fragmentary. Promotion of mitochondrial respiration by glutamate is related to its role as a key player for the MAS, for activation of the TCA cycle flux at the a-KG step, and to its role as a substrate (together with malate) for complex I respiration in the ETC. In addition to transfer of glutamate from the cytosol, mitochondrial glutamate is synthesized by transamination of a-KG produced by the TCA cycle, e.g. from lactate or pyruvate. 13, 116 For years, deamination and transamination of glutamate has been known to activate the TCA cycle flux. Anaplerotic transamination of amino acids, in particular of glutamate, has been proposed as a source of anaerobic energy during ischaemia. 117, 118 To our knowledge, the protective significance of this mechanism remains uncertain.
Because of the abundant amount of glutamate in the heart, 13 C-isotope enrichment of glutamate is used as a tool to assess activity of the TCA cycle. This important technique provides reliable estimates in steady-state conditions when the TCA cycle flux can be assumed to be rate limiting. During the non-steady-state condition of myocardial ischaemia, glutamate transfer across the mitochondrial membrane and the normally rapid exchange between mitochondrial a-KG and glutamate decrease, and may become rate limiting with a high risk of erroneous assessment of TCA cycle activity from the 13 C technique. 119 In addition, the sensitivity of glutamate estimation of the TCA cycle flux is limited by the higher glutamate content in the cytosolic than in the mitochondrial compartment. The evidence that glutamate is involved in the changes in cytosolic glucose metabolism during ischaemia is sparse. In isolated rat hearts, perfusion with glutamate and glutamine in supraphysiological concentrations increases tracer-estimated post-ischaemic de novo glycogen resynthesis. 120, 121 A similar finding has been reached in cultured astrocytes from the rat brain. 122, 123 The underlying mechanism differs from insulin-induced glycogen synthesis as it does not involve the phosphatidylinositol 3-kinase pathway. Data from a single study indicate that glutamate may inhibit opening of mPTP in liver mitochondria. 124 In kidney proximal tubule cells, intracellular accumulation of free fatty acids during hypoxia and reperfusion mediate reversible uncoupling of oxidative phosphorylation and opening of the mPTP. 125 Recently, it was shown that non-metabolized glutamate and malate alleviate this effect through competition with fatty acids for transport into the mitochondria. 126 Assuming that this mechanism is active in the heart, this antagonism may be of protective importance because it opposes the detrimental effects of high fatty acid concentrations on post-ischaemic cardiac function. 57 Glutamate loading of isolated adult cardiomyocytes induces better recovery after wash-off of metabolic inhibitors, 127 protects against ROS generation, and modifies the glutathione redox-state. 128 Postischaemic perfusion of the globally ischaemic heart with the supraphysiological glutamate concentrations used in cardioplegic solutions (20 mM or higher) reduces the myocardial infarct size in a dosedependent way. 22, 45 This infarct limiting effect was seen with glutamate administration during the first 10 min of reperfusion, 45 suggesting that glutamate may modify reperfusion injury during early reperfusion. Surprisingly, infarct reduction by glutamate was not followed by improved haemodynamic recovery. 22 The dissociation between infarct size and haemodynamic recovery is in agreement with previous results, 129 but the underlying mechanism remains unknown. Although a non-specific model phenomenon cannot be excluded, our results call for reconsideration of the use of high glutamate concentrations in cardioplegic solutions. IPC increases the intracellular glutamate concentration during ischaemia as does IPostC (unpublished data). In agreement with reports by others, 130 the tissue glutamate content decreased in both IPC and control hearts during post-ischaemic reperfusion, suggesting augmented glutamate oxidation. It is noteworthy that IPC reduced the interstitial glutamate concentration in the heart during reperfusion, 22 to the same degree as has been reported for brain tissue. 131 Extracellular glutamate measured by the concentration of the amino acid in cerebrospinal fluid is a strong predictor of progression of ischaemic tissue damage in stroke patients. 132 Taken together, the available data suggest that glutamate possesses cytoprotective effects in the heart. However, from our current understanding, it is not possible to formulate a cogent overall hypothesis of the effects of glutamate in protection against IR injury.
Cardioprotection by glutamine
Glutamate is transported between organs as the non-toxic amino acid glutamine released from skeletal muscles, intestines, and kidney, and subsequently converted to glutamate by glutaminase in the target organ. 133 Perfusion with a near physiological glutamine concentration during low-flow ischaemia augments the post-ischaemic tissue glutamate concentration, and improves cardiac output and energy metabolism. It is not validated that cardioprotection by glutamine is caused by an augmented oxidation of glutamate secondary to the increased tissue level. 134 Ischaemic cardioprotection is thought to be associated with optimized energy by adaptation of major pathways such as glycolysis, and glucose and fatty acid oxidation. Emerging evidence suggests that accessory glycolytic pathways involved in post-translational modification by glycosylation of proteins are of importance for the changes in intracellular metabolism that exerts cardioprotection. In the isolated rat heart, glutamine mediates cardioprotection through glycosylation of nucleocytoplasmic proteins by the O-linked N-acetylglucosamine pathway. 135 Protection by this pathway has been reviewed recently. 136, 137 Briefly, glucose and an amine group from glutamine converted to glutamate enter into the hexosamine biosynthesis pathway (HBP) by a glutamine-fructose-6-phosphate aminotransferase reaction resulting in synthesis of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is a sugar donor for glycosylation of proteins (O-GlcNAc-proteins) by a transferase enzyme (UDP-GlcNc:polypeptide b-N-acetylglucosaminyltransferase (OGT). O-linked glycosylation is a reversible, rapid, and dynamically cycling pathway with removal of UDP-GlcNAc from the modified protein by a hexosaminidase reaction. Activity of the HBP pathway and formation of UDP-GlcNAc are sensitive to changes in circulating glucose and glutamine concentrations.
138,139
O-GlcNAcylation confers cytoprotection in isolated hearts and cardiomyocytes by reducing cellular Ca 2+ overload and ROS production and diminishing of mPTP. 140 Recently, elevated levels of the OGT enzyme and O-linked glycosylated proteins have been found in the remote viable myocardium of infarcted mice, while deletion of OGT exacerbated dysfunction of the failing heart. 141 Glutamine-induced cardioprotection by O-linked glycosylation includes enhanced heat shock protein 70 expression.
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A single study has reported a remote-delayed cardioprotective effect of glutamine. In vivo intra-peritoneal injection of glutamine protected against IR injury in the isolated rat heart 18 h after administration 143 as evaluated by improved haemodynamic recovery and modified myocardial metabolism including preserved glutathione level. O-glycosylation of cardioprotective proteins was not reported. Remote IPC (RIPC) has been applied in the clinical setting, with reduction in myocardial injury reported in cardiac surgery 144 and in myocardial infarct patients treated with primary angioplasty. 145 It is tempting to speculate that changes in glutamine and glutamate metabolism may be involved in RIPC, either as part of the cardioprotective signal that is conveyed from the conditioned distant organ to the target tissue, or by O-glycosylation of local protective proteins in the ischaemic target organ. Despite increasing enthusiasm about an overall protective effect of glutamine administration to patients with critical illness, 146 the translation into a major clinical benefit remains to be documented.
Conclusion
From the available literature and our own findings that modulation of mitochondrial metabolism and respiration in the beating heart induce cardioprotection and affect cell survival, we have reviewed the underlying mechanisms of this phenomenon with a focus on direct inhibition of the MAS and the metabolic links and pathways for communication of bioenergetic states between the cytosolic and mitochondrial compartments. Inhibition of mitochondrial respiration by the MAS during lethal ischaemia and a gradual 'wake-up' at the start of reperfusion is concluded to be a pivotal mechanism of protection against IR injury. The finding that a simple chemical inhibitor of mitochondrial energy metabolism generates cardioprotection similar to that obtained after activation of inherent physiological mechanisms by IPC unlocks an encouraging future perspective for the development of pharmacological interventions.
